- Home
- VMRK vs BDX Comparison
VMRK vs BDX Comparison
Compare VMRK & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$65.29
N/A
Current Price
$188.20
Company Overview
Basic Information| Metric | VMRK | BDX |
|---|---|---|
| Founded | N/A | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6B | 43.0B |
| IPO Year | 1994 | 1998 |
Fundamental Metrics
Financial Performance| Metric | VMRK | BDX |
|---|---|---|
| Price | $65.29 | $188.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $186.00 |
| AVG Volume (30 Days) | N/A | ★ 1.7M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 8.09 | N/A |
| EPS | 0.54 | ★ 1.59 |
| Revenue | $2,701,075,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.02 |
| P/E Ratio | ★ N/A | $119.21 |
| Revenue Growth | 4.76 | ★ 8.24 |
| 52 Week Low | N/A | $140.11 |
| 52 Week High | N/A | $213.08 |
Technical Indicators
Market Signals| Indicator | VMRK | BDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.28 |
| Support Level | N/A | $141.69 |
| Resistance Level | N/A | $194.72 |
| Average True Range (ATR) | 0.00 | 3.83 |
| MACD | 0.00 | -0.52 |
| Stochastic Oscillator | 0.00 | 69.20 |
Price Performance
Historical Comparison VMRK
BDX
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.